Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...

Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent(TM) Oncomine(TM) Dx Target Test as a companion ...

Thermo Fisher Scientific Inc. TMO recently gained pre-market approval from the FDA for its Oncomine Dx Target Test as a companion diagnostic (CDx) to detect patients with epidermal growth factor ...

Thermo Fisher Scientific, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who ...

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the most undervalued large cap stocks to buy according to analysts. On July 3, Thermo Fisher Scientific announced that its Oncomine Dx Express Test, ...

The Oncomine Dx Target Test assesses tumor samples for the presence of biomarkers associated with three drug therapies approved to treat non-small cell lung cancer. Physicians can use the test to ...

The US Food and Drug Administration (FDA) has granted pre-market approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients with isocitrate ...

Objective：Oncomine TM Dx Target Test® (ODxTT) has emerged as a companion diagnosing system for advanced non-small-cell lung cancer (NSCLC) using next generation sequencing. However, the test results ...

Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer generates results in as little as 24 hours to support timely therapy decisions A patient’s tumor profile has the potential ...

Thermo Fisher Scientific Inc. is working with Daiichi Sankyo Co. Ltd. to develop a companion diagnostic (CDx) to identify non-small-cell lung cancer (NSCLC) patients with human epidermal growth factor ...